Browse > Article
http://dx.doi.org/10.3857/roj.2014.32.2.63

Patterns of failure and prognostic factors in resected extrahepatic bile duct cancer: implication for adjuvant radiotherapy  

Koo, Tae Ryool (Department of Radiation Oncology, Seoul National University College of Medicine)
Eom, Keun-Yong (Department of Radiation Oncology, Seoul National University College of Medicine)
Kim, In Ah (Department of Radiation Oncology, Seoul National University College of Medicine)
Cho, Jai Young (Department of Surgery, Seoul National University College of Medicine)
Yoon, Yoo-Seok (Department of Surgery, Seoul National University College of Medicine)
Hwang, Dae Wook (Department of Surgery, Seoul National University College of Medicine)
Han, Ho-Seong (Department of Surgery, Seoul National University College of Medicine)
Kim, Jae-Sung (Department of Radiation Oncology, Seoul National University College of Medicine)
Publication Information
Radiation Oncology Journal / v.32, no.2, 2014 , pp. 63-69 More about this Journal
Abstract
Purpose: To find the applicability of adjuvant radiotherapy for extrahepatic bile duct cancer (EBDC), we analyzed the pattern of failure and evaluate prognostic factors of locoregional failure after curative resection without adjuvant treatment. Materials and Methods: In 97 patients with resected EBDC, the location of tumor was classified as proximal (n = 26) and distal (n = 71), using the junction of the cystic duct and common hepatic duct as the dividing point. Locoregional failure sites were categorized as follows: the hepatoduodenal ligament and tumor bed, the celiac artery and superior mesenteric artery, and other sites. Results: The median follow-up time was 29 months for surviving patients. Three-year locoregional progression-free survival, progression-free survival, and overall survival rates were 50%, 42%, and 52%, respectively. Regarding initial failures, 79% and 81% were locoregional failures in proximal and distal EBDC patients, respectively. The most common site was the hepatoduodenal ligament and tumor bed. In the multivariate analysis, perineural invasion was associated with poor locoregional progression-free survival (p = 0.023) and progression-free survival (p = 0.012); and elevated postoperative CA19-9 (${\geq}37U/mL$) did with poor locoregional progression-free survival (p = 0.002), progression-free survival (p < 0.001) and overall survival (p < 0.001). Conclusion: Both proximal and distal EBDC showed remarkable proportion of locoregional failure. Perineural invasion and elevated postoperative CA19-9 were risk factors of locoregional failure. In these patients with high risk of locoregional failure, adjuvant radiotherapy could be considered to improve locoregional control.
Keywords
Bile duct neoplasms; Prognosis; Recurrence; Survival analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.   DOI   ScienceOn
2 Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230:663-71.   DOI   ScienceOn
3 Edge SB; American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.
4 Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003;98:1689-700.   DOI   ScienceOn
5 Park JH, Choi EK, Ahn SD, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2011;79:696-704.   DOI
6 Gwak HK, Kim WC, Kim HJ, Park JH. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys 2010;78:194-8.   DOI   ScienceOn
7 Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178-82.   DOI   ScienceOn
8 Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999;44:121-6.   DOI   ScienceOn
9 Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-9.   DOI   ScienceOn
10 Berger AC, Garcia M Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.   DOI   ScienceOn
11 Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011;81:e853-9.   DOI
12 He P, Shi JS, Chen WK, Wang ZR, Ren H, Li H. Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol 2002;8:943-6.   DOI
13 Nagakawa T, Mori K, Nakano T, et al. Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993;80: 619-21.   DOI   ScienceOn
14 Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384-94.   DOI   ScienceOn
15 Nakagohri T, Asano T, Kinoshita H, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003;27:289-93.   DOI
16 Harrison LB, Sessions RB, Hong WK. Head and neck cancer: a multidisciplinary approach. 3rd ed. Philadelphia, PA: Lipppincott Williams & Wilkins; 2009.
17 Im JH, Seong J, Lee J, et al. Postoperative radiotherapy dose correlates with locoregional control in patients with extrahepatic bile duct cancer. Radiat Oncol J 2014;32:7-13.   DOI
18 Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-97.   DOI   ScienceOn
19 Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-57.   DOI   ScienceOn
20 Koh HK, Park HJ, Kim K, Chie EK, Min HS, Ha SW. Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery. Radiat Oncol J 2012;30:197-204.   DOI